TuHURA Biosciences (NASDAQ:HURA) Announces Earnings Results, Misses Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) released its earnings results on Friday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports.

TuHURA Biosciences Stock Down 8.0%

NASDAQ HURA traded down $0.20 during trading on Friday, hitting $2.31. 613,892 shares of the stock traded hands, compared to its average volume of 817,524. The company has a market capitalization of $147.10 million, a P/E ratio of -3.67 and a beta of -0.01. The firm has a 50-day simple moving average of $2.14 and a 200-day simple moving average of $1.61. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.05.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HURA. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Rodman & Renshaw began coverage on TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating on the stock. Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Finally, Citizens Jmp began coverage on TuHURA Biosciences in a report on Monday, April 27th. They issued a “market outperform” rating and a $9.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Investors Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of TuHURA Biosciences by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of TuHURA Biosciences by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after acquiring an additional 39,710 shares during the last quarter. State Street Corp lifted its stake in shares of TuHURA Biosciences by 4.9% during the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares during the last quarter. Deutsche Bank AG raised its position in TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares in the last quarter. Finally, Barclays PLC raised its position in TuHURA Biosciences by 42.6% during the 4th quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after purchasing an additional 15,725 shares in the last quarter. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics using high?dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first?in?class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.